9 results about "Prostacyclin" patented technology

The invention discloses a combined evaluation method for in-vitro and in-vivo red fading and relieving effects of cosmetic raw materials, which comprises the following steps: in-vitro model evaluation: inducing a human immortalized umbilical vein endothelial cell model by adopting TNF-alpha, and detecting the secretion amount of a prostacyclin I2 factor to obtain a score of an in-vitro model; in-vivo model evaluation: adopting a chick embryo chorioallantoic membrane model, and obtaining a score of the in-vivo model according to the degree of vasoconstriction caused by the to-be-detected raw material sample acting on the chick embryo chorioallantoic membrane; and comprehensive evaluation: based on the score of the in-vitro model and the score of the in-vivo model, comprehensively evaluating the red fading and relieving efficacy of the raw material sample to be tested. According to the technical scheme, the defect that in the prior art, no cosmetic raw material soothing efficacy evaluation method for the vascular reactivity increasing mechanism exists is overcome, efficacy evaluation is more accurate, the method has the advantages of being comprehensive, short in test period, easy to operate, economical and convenient, and an effective reference basis is provided for screening and compounding schemes of red fading and soothing raw materials.

Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.

A treprostol derivative and its uses are provided. Specifically, a compound of formula (I) or a pharmaceutically acceptable salt thereof is provided, wherein each group is as defined in the specification. The compound of formula (I) or a pharmaceutically acceptable salt thereof can be used to treat pulmonary hypertension.

The present invention relates to a nebulizer kit, comprising a pharmaceutical composition including a prostaglandin, prostacyclin and the analogue thereof and a nebulizer to deliver a prostaglandin, prostaglandin analogue, prostacyclin or prostacyclin analogue with a higher drug delivery efficiency. Also disclosed are methods for treating a respiratory disease and heart failure, using the nebulizer kit disclosed herein.

Provided herein in some embodiments are pharmaceutical compositions comprising a prostacyclin (PGI2) receptor agonist selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1) and pharmaceutically acceptable salts, solvates, and hydrates thereof, as disclosed herein. In some embodiments the pharmaceutical compositions comprise a compound selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), and pharmaceutically acceptable salts, solvates, and hydrates thereof, in an amount equivalent to a therapeutically effective amount of Compound 1, the composition having a release rate by weight of the compound in an aqueous medium that is one or more of release rates (a), (b) and (c) as disclosed herein. The compositions of the present invention are useful in the treatment of PGI2 related disorders, such as those disclosed herein.

The invention discloses a dexheptane structure prostacyclin-loaded nano transdermal patch and a preparation method, the dexheptane structure prostacyclin-loaded nano transdermal patch comprises 10-30 parts of dexheptane precursor liposome, 10-20 parts of a prostacyclin nano-structure lipid carrier and 50-70 parts of an acrylate pressure-sensitive adhesive, the dexheptane precursor liposome comprises 8-12 parts of dexheptane and 36-54 parts of hydrogenated soya bean lecithin, and the prostacyclin nano-structure lipid carrier comprises a prostacyclin nano-structure lipid carrier and an acrylate pressure-sensitive adhesive. The prostacyclin injection comprises the following components in parts by weight: 36-54 parts of mannitol, 80-240 parts of absolute ethyl alcohol, 150-450 parts of purified water, 0.150-0.200 part of prostacyclin, 80-150 parts of glyceryl monostearate, 20-50 parts of oleic acid, 10-30 parts of soybean lecithin and the balance of purified water, wherein the total amount of the prostacyclin injection, the glyceryl monostearate, the oleic acid, the soybean lecithin and the purified water is 1000 parts. According to the invention, the dextroheptane is used as a functional penetration enhancing component in transdermal drug delivery, the dextroheptane and the prostacyclin are synergistically integrated in the nano-lipid carrier, the transdermal penetration rate and the cumulative penetration amount of the prostacyclin are improved, the treatment effect is improved, and continuous and stable release of the prostacyclin is realized under the combined action of the nano-structure lipid carrier and the patch matrix.

The application discloses a combined evaluation method for the in-vitro and in-vivo redness-reducing soothing effect of a cosmetic raw material, which comprises in-vitro model evaluation, adoption of a human immortalized umbilical vein endothelial cell model induced by TNF-alpha, acquisition of the in-vitro model score by detecting the secretion amount of prostacyclin I2 factor, in-vivo model evaluation, adoption of a chicken embryo chorioallantoic membrane model, acquisition of the in-vivo model score by the degree of blood vessel contraction caused by the action of the sample to be tested on the chicken embryo chorioallantoic membrane, and comprehensive evaluation of the redness-reducing soothing effect of the sample to be tested based on the in-vitro model score and the in-vivo model score. The technical scheme of the application makes up for the defect of the prior art that there is no cosmetic raw material soothing effect evaluation method for the mechanism of increased vascular reactivity, the effect evaluation is more accurate, and the method has the advantages of comprehensiveness, short test cycle, simple operation, economy and convenience, and provides an effective reference for the screening and compounding scheme of redness-reducing soothing raw materials.

The invention relates to the technical field of function testing of cosmetic raw materials, and particularly discloses a method and a model for evaluating in-vitro red fading and relieving effects of cosmetic raw materials, and the method comprises the following steps: inducing human immortalized umbilical vein vascular endothelial cells by adopting a TNF-alpha inducer to establish a red fading and relieving in-vitro model; the method specifically comprises the following steps: after inoculating and culturing human immortalized umbilical vein vascular endothelial cells, setting a control group, a modeling group, a positive drug group and a sample group, respectively adding special culture mediums into the control group and the modeling group, adding an epoxidase inhibitor into the positive drug group, adding a raw material sample to be detected into the sample group, and pre-treating; then adding a TNF-alpha inducer into each group except the control group, and carrying out induction culture; the prostacyclin I2 factor is adopted as a detection index to evaluate the red fading and relieving effects of the raw material sample to be detected. The method is short in test period, simple to operate, economical and convenient, and provides reliable data for further research of efficacy verification in the cosmetic industry.